Pfizer Ltd
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1]
It is the 3rd largest multinational pharmaceutical company in India.[2]
- Market Cap ₹ 17,387 Cr.
- Current Price ₹ 3,801
- High / Low ₹ 4,662 / 3,407
- Stock P/E 28.9
- Book Value ₹ 701
- Dividend Yield 0.92 %
- ROCE 26.2 %
- ROE 19.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 29.2%
Cons
- The company has delivered a poor sales growth of 4.26% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,093 | 1,049 | 1,112 | 1,853 | 2,012 | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | |
897 | 865 | 872 | 1,438 | 1,579 | 1,616 | 1,468 | 1,516 | 1,578 | 1,526 | 1,775 | 1,616 | |
Operating Profit | 197 | 184 | 239 | 414 | 433 | 350 | 501 | 566 | 574 | 712 | 836 | 809 |
OPM % | 18% | 18% | 22% | 22% | 22% | 18% | 25% | 27% | 27% | 32% | 32% | 33% |
92 | 519 | 109 | 44 | 97 | 232 | 114 | 167 | 183 | 81 | 63 | 134 | |
Interest | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 11 | 15 | 11 | 13 |
Depreciation | 10 | 8 | 8 | 250 | 58 | 63 | 66 | 71 | 103 | 109 | 115 | 106 |
Profit before tax | 278 | 694 | 340 | 207 | 470 | 517 | 548 | 660 | 642 | 669 | 773 | 824 |
Tax % | 33% | 27% | 35% | 66% | 35% | 35% | 34% | 35% | 21% | 26% | 21% | 24% |
Net Profit | 185 | 503 | 221 | 70 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 |
EPS in Rs | 61.86 | 168.62 | 74.01 | 15.26 | 66.67 | 73.62 | 78.71 | 93.79 | 111.29 | 108.77 | 133.90 | 136.38 |
Dividend Payout % | 20% | 19% | 486% | 82% | 22% | 27% | 25% | 24% | 297% | 32% | 26% | 29% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 4% |
3 Years: | 4% |
TTM: | -7% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 6% |
TTM: | -2% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | 9% |
3 Years: | -2% |
1 Year: | -11% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 18% |
3 Years: | 20% |
Last Year: | 20% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
30 | 30 | 30 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | |
Reserves | 1,275 | 1,665 | 629 | 1,927 | 2,118 | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 |
-0 | -0 | -0 | 2 | 2 | 2 | 2 | 2 | 2 | 63 | 39 | 41 | |
277 | 365 | 318 | 638 | 722 | 840 | 1,004 | 926 | 1,007 | 810 | 997 | 752 | |
Total Liabilities | 1,582 | 2,060 | 977 | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 |
31 | 26 | 20 | 944 | 925 | 902 | 950 | 886 | 973 | 894 | 869 | 749 | |
CWIP | 0 | 0 | 3 | 13 | 3 | 15 | 1 | -0 | 1 | 3 | 1 | 8 |
Investments | 48 | 46 | 44 | 43 | 37 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
1,502 | 1,988 | 909 | 1,614 | 1,923 | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | |
Total Assets | 1,582 | 2,060 | 977 | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
24 | -16 | 132 | 113 | 345 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | |
278 | 626 | 103 | 68 | -701 | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | |
-14 | -43 | -1,360 | -1 | -62 | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | |
Net Cash Flow | 288 | 567 | -1,125 | 181 | -417 | -3 | -17 | 23 | 1,690 | -1,613 | -88 | -26 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 47 | 49 | 57 | 32 | 26 | 20 | 29 | 30 | 29 | 18 | 17 | 23 |
Inventory Days | 186 | 181 | 148 | 191 | 167 | 148 | 147 | 189 | 198 | 199 | 173 | 175 |
Days Payable | 138 | 165 | 156 | 165 | 157 | 178 | 245 | 213 | 197 | 130 | 102 | 91 |
Cash Conversion Cycle | 95 | 65 | 49 | 58 | 36 | -10 | -69 | 6 | 31 | 87 | 89 | 107 |
Working Capital Days | 71 | 7 | 25 | 7 | -9 | -46 | -57 | -15 | -7 | 13 | -7 | 7 |
ROCE % | 23% | 19% | 29% | 24% | 22% | 17% | 21% | 23% | 20% | 23% | 29% | 26% |
Documents
Announcements
- Pfizer Limited - Results Of The Postal Ballot (E-Voting). 1d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 26 May
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
18 May - Company has decided to initiate a voluntary recall of( i) Magnex 1gm, 2gm;(ii) Magnex Forte 1.5gm, 3gm; (iii) Zosyn 4.5gm; and (iv)Magnamycin 250mg, 1gm, 2gm …
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
16 May - Compliance Report for the year ended March 31, 2023, issued by Mr. K. G. Saraf, Practicing Company Secretary. We request you to kindly take the …
- Disclosure Under Regulation 23(9) Of The SEBI (LODR) Regulations, 2015 ('Listing Regulations') 15 May
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Aug 2020TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Product Portfolio
Presently, the company sells ~150 different products across 15+ therapeutic areas viz. anti-allergic, anti-diabetic, anti-infectives, cardiovascular, gastrointestinal, neurology, pain, respiratory, vitamin/minerals, antibiotics, etc.[1][2]